Last updated: 07/17/2024 17:19:23
Single doses of GSK3008348 in idiopathic pulmonary fibrosis (IPF) participants using positron emission tomography (PET) imaging
GSK study ID
204715
EudraCT ID
EU CT Number
Not applicable
Trial status
Other
Other
Trial overview
Official title: A study of single doses to evaluate the safety, tolerability, pharmacokinetics and target engagement of nebulised GSK3008348 in idiopathic pulmonary fibrosis patients, using positron emission tomography (PET) imaging
Trial description: GSK3008348 is being developed as a treatment for IPF. A first-time-in-human study showed that single nebulized doses of 1−3000 micrograms (mcg) GSK3008348 in healthy volunteers were well tolerated, with pharmacokinetic (PK) exposures within the defined limits set in the protocol. The proposed study is a 2-cohort study of single doses, intended to evaluate the safety, tolerability and PK of the drug in participants with IPF not currently treated with pirfenidone or nintedanib, and to obtain preliminary information on target engagement. Cohort 1 will be a 2-period, randomized, double-blind, placebo-controlled group with at least 7 days washout between doses, and follow-up period of up to 7-14 days. Cohort 2 is optional. It will be designed to further explore safety and to provide additional information on the target engagement profile of GSK3008348. The total duration of the study will be up to 62 days.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Volume of distribution (VT) (not corrected for air volume) at approximately 30 minutes (min) post-dose compared to pre-dose measured by PET
Timeframe: Pre-dose and 30 min
Number of subjects with any adverse event (AE) and any serious adverse event (SAE)
Timeframe: Up to 42 days
Systolic and diastolic blood pressure (BP) as a measure of safety
Timeframe: Up to 72 days
Heart rate (HR) as a measure of safety
Timeframe: Up to 72 days
Body temperature as a measure of safety
Timeframe: Up to 72 days
Respiratory rate as a measure of safety
Timeframe: Up to 72 days
12-lead electrocardiogram (ECG) as a measure of safety
Timeframe: Up to 72 days
Number of subjects with abnormal hematology parameters
Timeframe: Up to 72 days
Number of subjects with abnormal clinical chemistry parameters
Timeframe: Up to 72 days
Number of subjects with abnormal urinalysis parameters
Timeframe: Up to 72 days
Forced expiratory volume in 1 second (FEV1)
Timeframe: Up to 72 days
Forced vital capacity (FVC)
Timeframe: Up to 72 days
Diffusing capacity of the lungs for carbon monoxide (DLCO)
Timeframe: 24 hrs post-dose in period 1.
Secondary outcomes:
Area under the plasma concentration-time curve from zero (0) hrs to time (t) [AUC(0-t)] of GSK3008348
Timeframe: Period 1: at pre-dose, 15 and 30 min, 1, 2, 4, 8, 12, 18 and 24 hrs after the start of nebulization, Period 2: at pre-dose, 15 and 30 min, 2 and 4 hrs post-dose on Day 1, and on arrival and discharge from imaging unit on Day 2.
Area under the plasma concentration-time curve from zero (0) hrs to infinity (inf) AUC [(0-inf)]
Timeframe: Period 1: at pre-dose, 15 and 30 min, 1, 2, 4, 8, 12, 18 and 24 hrs after the start of nebulization, Period 2: at pre-dose, 15 and 30 min, 2 and 4 hrs post-dose on Day 1, and on arrival and discharge from imaging unit on Day 2.
Maximum observed plasma drug concentration (Cmax) of GSK3008348
Timeframe: Period 1: at pre-dose, 15 and 30 min, 1, 2, 4, 8, 12, 18 and 24 hrs after the start of nebulization, Period 2: at pre-dose, 15 and 30 min, 2 and 4 hrs post-dose on Day 1, and on arrival and discharge from imaging unit on Day 2.
Time to maximum observed plasma drug concentration (Tmax) of GSK3008348
Timeframe: Period 1: at pre-dose, 15 and 30 min, 1, 2, 4, 8, 12, 18 and 24 hrs after the start of nebulization, Period 2: at pre-dose, 15 and 30 min, 2 and 4 hrs post-dose on Day 1, and on arrival and discharge from imaging unit on Day 2.
Terminal half-life (T1/2) of GSK3008348
Timeframe: Period 1: at pre-dose, 15 and 30 min, 1, 2, 4, 8, 12, 18 and 24 hrs after the start of nebulization, Period 2: at pre-dose, 15 and 30 min, 2 and 4 hrs post-dose on Day 1, and on arrival and discharge from imaging unit on Day 2.
VT at up to 28 hrs post-dose compared to pre-dose measured by PET
Timeframe: 28 hrs post-dose
Interventions:
Enrollment:
8
Primary completion date:
2018-04-07
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Toby M Maher; Juliet K Simpson; Joanna C Porter; Frederick J Wilson; Robert Chan; Rhena Eames; Yi Cui; Sarah Siederer; Simon Parry; Julia Kenny; Robert J. Slack; Jagdeep Sahota; Lyn Paul; Peter Saunders; Philip L Molyneaux; Pauline Lukey; Gaia Rizzo; Graham E Searle; Richard P Marshall; Azeem Saleem; Arthur R. Kang’ombe; David Fairman; William A Fahy; Mitra Vahdati-Bolouri.A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor .Respir Res.2020;21(1):75
DOI: 10.1186/s12931-020-01339-7
PMID: 32216814
Medical condition
Idiopathic Pulmonary Fibrosis
Product
GSK2634673, GSK3008348
Collaborators
Not applicable
Study date(s)
June 2017 to July 2018
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
50+ years
Accepts healthy volunteers
No
- Male participants aged >= 50 years, and female participants aged >=55 years, at the time of signing the informed consent.
- Diagnosis of definite or probable IPF as determined by a responsible and experienced chest physician and based on established criteria defined by the American Thoracic Society/European Respiratory Society Internationale Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
- ALT and bilirubin > 1.5x upper limit of normal (ULN; isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin < 35 percent).
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
Inclusion and exclusion criteria
Inclusion criteria:
- Male participants aged >= 50 years, and female participants aged >=55 years, at the time of signing the informed consent.
- Diagnosis of definite or probable IPF as determined by a responsible and experienced chest physician and based on established criteria defined by the American Thoracic Society/European Respiratory Society Internationale Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
- Ambulant and capable of attending outpatient visits.
- FVC > 50 percent predicted and DLCO > 40 percent predicted.
- Body weight >= 45 kilograms (kg) and body mass index (BMI) within the range 18.0–35.0 kg/square meter (inclusive).
- Male and female
- Male participants: A male participant must agree to use contraception as detailed in this protocol during the study and for at least 90 days after the follow up visit, and refrain from donating sperm during this period.
- Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and not a woman of childbearing potential (WOCBP) as defined in the protocol.
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions, listed in the informed consent form (ICF) and in this protocol.
Exclusion criteria:
- ALT and bilirubin > 1.5x upper limit of normal (ULN; isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin < 35 percent).
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- QT corrected (QTc) > 450 milliseconds (msec), or QTc > 480 msec in participants with Bundle Branch Block.
- Current IPF exacerbation, or upper or lower respiratory tract infection on admission to the clinical unit.
- History of or suffers from claustrophobia, or unable to lie flat and still on their back for up to 2 hrs in the PET scanner.
- Extent of emphysema greater than the extent of fibrotic change on High-Resolution Computed Tomography (HRCT) scan, based on investigator judgment.
- FEV1/FVC ratio < 0.70 at screening (post-bronchodilator).
- History of sensitivity to the study treatment, or components thereof, or a history of drug or other allergy that, in the opinion of the investigators or Medical Monitor, contraindicates their participation.
- Any current oro-pharygneal disease or disorders as judged by the investigator.
- Currently taking pirfenidone or nintedanib, or received pirfenidone or nintedanib within 30 days of the first dose of study treatment.
- Taken, within 7 days or 5 half-lives (whichever is longer) before the first dose of study treatment, organic anion transporter (OAT) substrates with a narrow therapeutic index (example: methotrexate and tenofovir), vitamins, or dietary or herbal supplements, unless in the opinion of the investigator and sponsor the supplement will not interfere with the study medication.
- Long-term continuous home oxygen therapy (use of oxygen that is only intermittent and for symptom relief is acceptable).
- Participation in a clinical trial and receipt of an investigational medicinal product within the following time period before the first dose in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than 4 new investigational medicinal products within 12 months before the first dose.
- Presence of Hepatitis B surface antigen (HBsAg) at screening, or positive Hepatitis C antibody test result at screening or within 3 months before the first dose of study treatment. Note: participants with a positive Hepatitis C antibody test because of previous, resolved disease can be enrolled if a confirmatory negative Hepatitis C Ribonucleic Acid (RNA) test is obtained.
- Previous or current exposure to animals that may harbour Food and Mouth Disease Virus (FMDV2).
- Previous long term (>= 3 months) residence in a country where FMDV2 is endemic (such as certain areas of Africa, Asia and South America.
- Where participation in the study would result in loss of blood or blood products in excess of 500 milliliter (mL) within 56 days.
- History of drug or alcohol abuse that in the opinion of the investigator affects their participation in the study.
- Exposure to ionizing radiation in excess of 10 Millisievert (mSv) above background over the previous 3 year period as a result of occupational exposure or previous participation in research studies. Clinically justified (therapeutic or diagnostic) exposures are not included in the exposure calculation.
Trial location(s)
Study documents
No study documents available.
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Other
Actual primary completion date
2018-04-07
Actual study completion date
2018-18-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website